ERBB2 and breast cancer: The EMT status of CTCs in patients with breast cancer is dependent on the breast cancer subtype: Mesenchymal CTCs are prevalent in triple‐negative and HER2‐positive breast cancer patients, whereas CTCs in lobular breast cancer patients are predominantly epithelial (Yu et al., 2013).